(1) To establish a leading preclinical R&D alliance in Taiwan. (2) To integrate the core strengths of five major R&D institutions in Taiwan: National Center for Biomodels (NCB) of the National Institutes of Applied Research, Biomedical Translation Research Center of Academia Sinica, Industrial Technology Research Institute (ITRI), Development Center for Biotechnology (DCB), and National Health Research Institutes. (3) To provide a complete one-stop CRO service, accelerating the translation and industrialization of innovative achievements in biotechnology and medicine.
Space Peptides
Headquartered in Switzerland with global operations, Space Peptides provides End-to-End pharmaceutical Peptide CRDMO services at Premium Speed & Quality – covering discovery, process development, and GMP manufacturing. In addition, our portfolio comprises a broad range of generic Peptide APIs.
Shanghai Taichu Biotechnology Co., Ltd.
Taichu group was founded in 2020, providing contract research, development and manufacturing services to pharmaceutical and biotech companies. Our service platforms include early discovery and design of complex antibodies such as multispecific antibodies, nanobodies, fusion proteins etc. Our GLP- and AAALAC- certified animal facility provides preclinical studies (PK/PD), safety evaluation (Toxicology) for a various modality of drug candidates, such as small molecules, biologics, ADC, CGT products, and RNAi, ASO, mRNA molecules. For development and manufacturing of complex antibodies, our CDMO (Tarlead) has experienced teams, well-established laboratories and facility for process development, drug substance production and drug product manufacturing, ready to meet your needs and timelines. | Taichu Group is a biotechology enterprise with a core advantage in “CRO+CDMO integrated services”, providing end-to-end solutions for global innovative drug development from early discovery through preclinical research. Headquartered in Shanghai’s Lingang Special Area, the Group operates through its subsidiaries: Taichu Bio (Pre-Clinical Research), AceMab Ltd (Antibody Discovery & Design), Tarlead Biologics (Biologics Development & Manufacturing), TJR Bio (Nucleic Acid Drug Process & Manufacturing), and Taichu (Shenzhen) (Innovative Therapeutic Development Advisory). Guided by the philosophy “Advocate of Ethics and Integrity, Quest for Verity”, we streamline R&D workflows and accelerate therapeutic advancement for global partners. Our synergistic service model bridges key gaps between discovery and commercialization, reinforcing our role as a strategic enabler in the biopharmaceutical innovation value chain.
SanaClis CRO
SanaClis CRO – Founded in 2000, SanaClis is a full-service global CRO with strong in-house clinical supply chain, logistics, and sourcing capabilities. We support clinical trials worldwide across the full study lifecycle and can operate as either a full-service or functional service provider, depending on sponsor needs. We have delivered clinical trial projects for sponsors ranging from virtual biotech to top 10 pharmaceutical companies, combining operational rigor with responsive execution and a focus on quality and predictable delivery. SanaClis provides CRO and clinical supply chain services across all therapeutic areas, with coverage across Europe (including the UK), USA (Americas) and Asia. We also bring deep operational experience in Central and Eastern Europe (CEE), supporting strong patient access and reliable site performance. To enable global distribution, SanaClis operates a network of privately owned, GMP- and GDP-certified depots strategically located worldwide. Our facilities support ambient and cold-chain storage, as well as packaging, labeling, and distribution services to protect product integrity throughout the IMP cold chain. CRO Services: Project Management, Clinical Monitoring, Site Management, Regulatory, Medical Writing, Data Management, Biostatistics, Pharmacovigilance, Medical Monitoring, Quality Management, Decentralized Trials. Clinical Supply Chain Services: Storage and Distribution, Secondary Packaging and Labelling, Global Strategic Sourcing, Qualified Person Services, Customs and Brokerage, SIMS – Inventory Management, Direct to Patient Services. Please reach out to Matt Delaney, Vice President of Business Development for the Americas region, email: matt.delaney@sanaclis.com or by phone at: 1 805 798-0060. Matt resides in San Diego, Ca.
Richmond Pharmacology
Richmond Pharmacology is a leading UK-based contract research organisation (CRO) providing comprehensive clinical research services from First-in-Human (FIH) and First-in-Patient (FIP) through to Phase III studies. For over two decades, we have partnered with pharmaceutical and biotechnology companies globally — particularly across the United States, Europe, and Japan — to deliver faster answers and empower smarter development decisions. Operating from a state-of-the-art clinical pharmacology unit in London, we integrate real-world clinical expertise, regulatory foresight, and operational excellence to support the successful delivery of complex clinical development programmes. Faster Answers for Smarter Decisions At Richmond Pharmacology, “Faster Answers” is our guiding principle. Through a combination of expert-led study design, agile operational models, and strategic regulatory insight, we enable sponsors to generate high-quality data earlier, accelerating programme timelines and reducing development risk. Our Core Expertise Includes: First-in-Human (FIH), First-in-Patient (FIP), and Clinical Development up to Phase III: Extensive experience managing trials from initial dosing through proof-of-concept and pivotal Phase III studies, across a broad range of therapeutic areas. Gene Editing and Gene Silencing Studies: Richmond Pharmacology is proud to support cutting-edge research in advanced therapeutic modalities, including CRISPR-Cas9 genome editing and RNA interference (RNAi)-based gene silencing, helping innovators bring transformative medicines to patients faster. Patient and Healthy Volunteer Studies: Our work spans both healthy volunteer and patient-focused research, with a strategic emphasis towards increasing patient-centric trials to better reflect real-world treatment needs. Rare and Orphan Disease Trials: We are recognised for our ability to design and conduct trials for rare and ultra-rare conditions, navigating recruitment and operational complexities with sensitivity and precision. Bridging Studies: Richmond Pharmacology is a leader in Japanese–European bridging studies, providing critical data to support global strategies. Cardiovascular, Metabolic, and Central Nervous System (CNS) Disorders: Specialist expertise in diseases such as cardiovascular disease (CVD), chronic kidney disease (CKD), hyperlipidaemia, non-alcoholic steatohepatitis (NASH), diabetes, and neurodegenerative or psychiatric disorders. Complex and Adaptive Trial Designs: Expertise in designing seamless adaptive protocols, umbrella trials, and novel methodologies that optimise development pathways while preserving scientific and regulatory integrity. Patient and Public Involvement (PPI): We embed Patient and Public Involvement across study planning and execution, ensuring trial designs are informed by patient perspectives to enhance engagement, experience, and outcomes. Regulatory Strategy and Scientific Consultancy: Richmond Pharmacology provides scientific and regulatory consultancy services, guiding sponsors through regulatory interactions and optimising study designs for approvals in the UK, US, and Europe. Why Partner with Richmond Pharmacology? Our experienced team, operational flexibility, and focus on scientific excellence make Richmond Pharmacology a trusted partner for companies seeking faster, smarter clinical development. Whether advancing a novel genetic therapy, accelerating a rare disease treatment, or bridging critical data across regions, we provide the solutions needed to move innovative therapies forward. For more information, please visit www.richmondpharmacology.com
Profil GmbH
Profil is the world’s leading CRO in metabolic research. As a full-service provider, we conduct early phase clinical trials within the indications of obesity, (pre)diabetes, and diabetes complications. We offer an unrivaled combination of science and professional conduct. This unique combination allows us to design and carry out best-in-class clinical trials for our clients. Our in-house scientific expertise covers pharmacology, obesity and prediabetes, nutritional sciences, cardiometbolic research, hepatology, endocrinology, the entire spectrum of diabetes complications, cell and molecular biology as well as metabolic monitoring and medical technology. One of our core technologies is the hyperinsulinemic euglycemic clamp, used to address action profiles of insulin and insulin analogues, beta cell function and insulin sensitivity. To address human metabolic pathways glucose clamp studies are combined with isotope dilution techniques and tissue biopsies. To be able to offer the best services for any glucose clamping setup, we have developed ClampArt, the next generation of glucose clamping. By owning a continuously updated database with entries of more than 30.000 well characterized individuals (healthy, healthy at-risk, type 1 and type 2 diabetes), we can recruit even the most complex clinical trials. We have a fully GMP certified pharmacy and in-house clinics with 60 beds and holds expertise in Data Management & Statistics and Regulatory Affairs.
Preclina Inc
Immune Specialists’ Research Service CRO: [ Booth # 4158] Preclina is a non-clinical CRO with a fully-integrated drug discovery platform specializing in Immunology. We offer a portfolio of models for efficacy pharmacology studies in autoimmunity, immuno-oncology, and transplantation immunology. Our platforms include humanized mouse models recapitulating autoimmune diseases and humanized tumor xenografts, enabling preclinical evaluation of biologics, cell therapies, and novel immunotherapies. With over 20 years of expertise in immunology, immunotoxicology, and bioanalysis, Preclina delivers integrated, customizable solutions with a focus on scientific rigor, speed, and cost-efficiency. Our advanced approaches help accelerate drug discovery and reduce development risk. We serve as a “Bridging Specialist” connecting non-clinical and clinical stages, supporting biotech and pharma partners in optimizing pipelines and making faster, smarter decisions in immunology drug development. Meet us at Booth # 4158. Our Preclinical Services: ● Comprehensive in vivo efficacy pharmacology services utilizing well-established autoimmune and inflammatory disease models, augmented by pioneering, technically advanced humanized autoimmune disease model platforms ● Humanized mouse models for immunotherapeutic development and pathogenesis research in oncology and transplantation immunology fields ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and the fastest results [PreVIVO™ Platform] Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Autoimmune Specialists’ Research Service CRO: Preclina is a non-clinical CRO specialized in autoimune and inflammatory disorders, providing the utmost quality services for novel drug development at the lightning speed, highest quality, and reasonable cost. In the global market of immune disease therapeutics, which shows explosive growth, Preclina Inc is a leading company that supports bio and pharmaceutical companies to secure new drug development competitiveness by providing the highest quality evaluation results at the fastest speed for the optimization processes of candidate compounds. Our scientific expertise in autoimmune and inflammatory diseases has been accumulated over 20 years. Scientists in Preclina provide well-established service repertoire mostly based on therapeutic efficacy evaluation, and effectively designed support for drug development processes. We strive to satisfy our clients by providing innovative integrated modular platform of investigation that permits robust results with lightning speed. [Our preclinical services] ● In vivo efficacy pharmacology using disease models recapitulating autoimmune and inflammatory disorders ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and fastest track results (Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA) ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Preclina is a global leading non-clinical CRO that supports bio and pharmaceutical companies to secure new drug development competitiveness by providing the highest quality evaluation results at the fastest speed for the optimization processes of candidate compounds. Our scientific expertise in autoimmune and inflammatory diseases has been accumulated over 20 years. Scientists in Preclina provide well-established service repertoire mostly based on therapeutic efficacy evaluation, and effectively designed support for drug development processes. We’re strengthening our leadership in immunological research by broadening our portfolio with sophisticated humanized mouse models, specifically optimized for oncology drug development. We strive to satisfy our clients by providing innovative integrated modular platform of investigation that permits robust results with lightning speed. Our preclinical services: ● In vivo efficacy pharmacology using disease models recapitulating autoimmune and inflammatory disorders ● Humanized mouse models for immunotherapeutic development and pathogenesis research in oncology and transplantation immunology fields ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and fastest track results Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Immune Specialists’ Research Service CRO: [ Booth #3816] Predict Your Clinical Success with “World’s First” Humanized Models Preclina is a “Bridging Specialist” that eliminates the uncertainty of the translational gap. We provide the high-fidelity data needed to turn early-stage assets into clinical success stories. 1. Proven Excellence in Immunology – Expertise: Over 20 years specializing in immunology, immunotoxicology, and bioanalysis. – Track Record: Contributed to $600M+ global license-out deals. – Reliability: Supported multiple assets achieving final FDA approval. 2. The PreHu™ Advantage: Unrivaled Predictive Power Gain an exclusive competitive edge with our quartet of World’s First & Pioneering commercialized humanized disease models: – World’s First Lineup: Our peer-reviewed models for Psoriasis, Atopic Dermatitis, BILF, and DSS-induced Colitis are the first of their kind commercialized globally. – Peer-Reviewed Authority: All four models are published in leading journals, ensuring high reproducibility and scientific rigor. – Translational Relevance: These platforms recapitulate the human immune system in a patient-like environment to accurately validate biologics and cell therapies. 3. Operational Speed & Strategy PreVIVO™ Platform: Access modular services (PrePsora, PreBILFi, PreNASHa, etc.) for the fastest, most consistent data. – Risk Reduction: Integrated services encompass lead selection to candidate development, dramatically reducing late-stage failure rates. – Strategic Grant: The PreTrial™ Program offers exclusive grant support to qualified companies to bridge the “PoC Hurdle” and boost asset valuation. Consult with our Global Business Development team to de-risk your pipeline today [ Humanized Mouse Model Platform (PreHu™) ] 1. Humanized CDX/PDX (Patient-Derived Xenograft)-Based Efficacy Services : This platform implants tumor cells/tissues into humanized mice for bio-pharmaceutical efficacy evaluations in a patient-like environment, crucial for immuno-oncology and cell therapy assessments. – Humanized CDX/PDX Model – Humanized PBMC/HSc Model – GvHD Model 2. Humanized Autoimmune Disease / Fibrosis Mouse Model : We have pioneered the world’s first service platform with four or more humanized autoimmune disease models, providing essential preclinical services for the development of biopharmaceuticals, such as antibody drugs and cell therapies. – Humanized Ulcerative Colitis (UC) Model – Humanized Pulmonary Fibrosis (IPF) Model – Humanized Psoriasis Model – Humanized Atopic Dermatitis Model [Efficacy Evaluation Pharmacology Services (PreVIVO™) ] 1. Arthritis Research Service: Preclina’s service not only includes all essential models for evaluating the efficacy in the development of therapeutic agents for rheumatoid arthritis but also provides the key model for osteoarthritis – CIA Model / CAIA Model / ACLT Model 2. Fibrosis Research Service: With extensive expertise in immunology and fibrosis research, we have the flexibility to lead drug efficacy assessment projects with in-depth insights, maximizing the potential for success in new drug development. – BILF Model / BISF Model / MASH Model 3. Atopic Dermatitis & Psoriasis Research Service: Preclina provides specialized inflammatory skin disease models to support preclinical and mechanistic research in dermatology. These models include psoriasis, atopic dermatitis, and hypersensitivity disorders, enabling precise evaluation through mRNA analysis, protein assays, histopathology, and cellular assessments. With internationally standardized read-outs and customized research services, our models enhance the success rate of new drug development. – Imiquimod-Induced Psoriasis / IL-23-Induced Psoriasis Models – Oxazolone-Induced AD / House Dust Mite-Induced AD Models 4. Inflammatory Bowel Disease Research Service : Preclina provides specialized models for inflammatory bowel disease (IBD) research. These models include the ulcerative colitis model (Dextran Sodium Sulfate, DSS-induced colitis) and the Crohn’s disease model (Dinitrobenzene Sulfonic Acid, DNBS-induced colitis). These models accurately replicate disease onset and progression, enabling comprehensive disease activity index (DAI) assessments, histopathologic evaluations, biomarker analyses, and toxicity assessments. – DSS-Induced Colitis / DNBS-Induced Colitis Models 5. Lupus Research Service: Preclina provides key animal models for lupus and Sjogren syndrome research. For lupus, it supports the development of new drugs targeting B lymphocytes, cell surface molecules, signaling pathway proteins, and regulatory cytokines. It also offers a mouse model for Sjogren syndrome. – MRL/lpr Lupus Model / NZBW F1 Lupus Model 6. Neuroscience Research Service: Preclina provides a specialized EAE (Experimental Autoimmune Encephalomyelitis) animal model to support preclinical research and mechanistic studies on multiple sclerosis (MS). In particular, the MOG-induced EAE mouse model serves as a standard model that closely resembles the inflammatory pathogenesis of MS driven by autoimmune mechanisms, making it widely utilized for evaluating disease progression and treatment responses. – MOG EAE Model / PLP EAE Model [Non-GLP Toxicology service & ADME-PK ] Customized PK/ADME-Tox evaluation services for dramatically enhancing the potential for successful drug development.
PharSafer
Founded in 2003 by Dr Graeme Ladds, PharSafer® is a specialist Contract Research Organisation (CRO) in Global Clinical and Post Marketing Drug Safety, and Medical Services, with a wealth of experience in Pharmacovigilance, Auditing and Medical Affairs – and the various, numerous and extensive legal safety/medical obligations for licence holders to comply with – as well as Regulatory Strategy for the best methods for obtaining scientific advice concerning licence submissions and approvals. Together with our sister company which focuses on Training: SaPhar, PharSafer® continuously seeks new and innovative ways to provide added value for our global clients – going above and beyond expectations and optimising processes and procedures involved with clinical and post marketing drug safety and licencing approach. Our ability to offer first-class services in Pharmacovigilance, Regulatory Affairs, Training, Auditing, Medical Affairs and IT Informatics means that, for many clients, we operate as their Pharmacovigilance and Medical Departments – guiding them through the labyrinth of drug safety and medical legislation, all in the interests of ensuring patient safety and client compliance. We love what we do. We love finding solutions. Quite simply, we are by far… Your leading partner in Drug Safety. | PharSafer is a Global CRO specialising in Clinical & Post Marketing Pharmacovigilance; Medical Affairs; Training; Auditing; IT Informatics and Regulatory Intelligence. PharSafer have been operating for the last 23 years growing annually and helping take Companies from their clinical to post-marketing phases and many clients have been with us over 10 years now. PharSafer have attended over 100 inspections on behalf of clients to aid their compliance and ensure Regulatory Authorities are satisfied with the activities being performed. PharSafer are also an innovative Company designing validated and automated systems to provide cost-effective solutions for clients and ensure Regulatory compliant systems. Our client base is truly global being in all continents and for clients that have drugs; devices; vaccines; biologics; advanced therapies; biosimilars; herbal and cosmetics. Our Team within the Company are very experienced (many with over 15 years experience) aided by our sister training Company (SaPhar) to provide new updates for clients on country specific regulations with regular monthly contacts and comments going to all clients. We would be happy to engage with you and talk about product development; product expansions into new countries; product launches and perform all of the activities mentioned above. Please review of website and we look forward to engaging with you personally.